GSK takes option on ChemoCentryx's Crohn's candidate
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is paying a £35 million option exercise fee to ChemoCentryx for an exclusive licence to develop further and globally commercialise Traficet-EN (CCX282-B), an oral antagonist of the CCR9 chemokine receptor for the treatment of inflammatory bowel diseases, including Crohn's disease.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.